Company Announcements - 2019
Appendix 4E, 4G and Corporate Governance Statement23 August 2019
Analytica presents its Preliminary Final Report, Corporate Governance Statement, and Appendix 4G.
Appendix 4C31 July 2019
Analytica presents its quarterly cash flow report to 30 June 2019.
Compliance Documents from Entitlement Offer7 June 2019
Analytica presents the following compliance documents from the recent Entitlement Offer.
Entitlement offer Raises $913k5 June 2019
Analytica is pleased to announce that it has completed its 1 for 6 pro-rata, non-renounceable entitlement offer announced on 10 May 2019, raising approximately $913,000.
Notice of Option Expiry22 May 2019
Analytica gives notice of unlisted options expiring 22 May 2019.
Entitlement Offer10 May 2019
A pro-rata, non-renounceable entitlement offer to raise up to ~$2.7m (before offer costs).
Appendix 4C30 April 2019
Analytica presents its quarterly cash flow report to 31 March 2019.
CE Mark for Pelvic Organ Prolapse18 April 2019
The PeriCoach system is now CE-Marked to assist in the conservative treatment of Pelvic Organ Prolapse in addition to urinary incontinence.
R&D Tax Incentive Receipt28 March 2019
Analytica is pleased to announce the receipt of $745k from the Australian Taxation Office under the Research and Development incentive related to the financial year to 30th June 2018.
Appendix 4D - Half Year Report27 February 2019
Analytica presents its Appendix 4D - Half year results to 31 December 2018.
Expiry of Unlisted Options13 February 2019
The Company advises that 5 million unlisted options at exercise price $0.0439 expired on 5pm 12 February 2019.
Appendix 4C31 January 2019
Analytica presents its quarterly cash flow report to 31 December 2018.